Temsirolimus + IFN‐α vs IFN (+ placebo) (targeted agent + classic immunotherapy versus classic immunotherapy)
Progression‐free survival · Treatment‐naïve metastatic renal cell carcinoma (any cell type)
Temsirolimus + IFN‐α may leads to lower progression‐free survival (absolute effect size estimates based on… compared with IFN‐α (targeted agent + classic immunotherapy versus classic… (low certainty).
1 finding from 1 review
- HR 0.76 [0.62, 0.93]1 study · 417 participantsLow